Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. HOOD
10. IBM

Go back to Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress

Fate Therapeutics (FATE) Misses Q4 EPS by 5c

February 28, 2022 4:27 PM EST

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.72), $0.05 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $10.73 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

... More